309285-78-7

Usage

Properties

Potential pharmacological and therapeutic properties
Belongs to the class of benzothiazole derivatives
Potential anti-inflammatory, anticancer, antimicrobial, and antiviral activities
Contains piperazine and sulfonyl groups
Potential for use as a CNS drug or ligand in drug-target interactions
Potential applications in the development of new drugs for various diseases

Specific content

Chemical structure: Contains benzothiazole ring with p-tolylsulfonyl and piperazin-1-yl groups attached
Potential pharmacological activities: Anti-inflammatory, anticancer, antimicrobial, and antiviral
Potential uses: CNS drug, drug-target interactions, new drug development
Importance: Valuable molecule for future research and pharmaceutical development

Upstream product

• 110-85-0 piperazine 
• 615-20-3 2-chlorobenzo[d][1,3]thiazole 
• 98-59-9 p-toluenesulfonyl chloride 
• 232263-41-1 ethyl 4-(benzothiazol-2-yl)-piperazin-1-carboxylate 
• 55745-83-0 2-piperazinobenzothiazole 

Relevant academic research and scientific papers

Aqueous, One-Pot, Three-Component Reaction for Efficient Synthesis of 2-[4-(Arylsulfonyl)piperazin-1-yl]-1,3-benzothiazole, -1 H -benzimidazole, or -1,3-benzoxazole Derivatives

A simple and efficient synthetic protocol has been developed involving a one-pot three-component reaction of a 2-chlorobenzazole, piperazine, and an arenesulfonyl chloride under aqueous conditions at room temperature in the absence of a catalyst, ligand, or base. By using this protocol, a variety of 2-[4-(arylsulfonyl)piperazin-1-yl]-1,3-benzothiazole, -1 H -benzimidazole, and -1,3-benzoxazole derivatives were synthesized in excellent yields.

Synthesis and biological analysis of benzazol-2-yl piperazine sulfonamides as 11β-hydroxysteroid dehydrogenase 1 inhibitors

In the last decade the inhibition of the enzyme 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) emerged as a promising new strategy to treat diabetes and several metabolic syndrome phenotypes. Using a molecular modeling approach and classical bioisosteric studies, we discovered a new class of 11β-HSD1 inhibitors bearing an arylsulfonylpiperazine scaffold. Optimization of the initial lead resulted in compound 11 that selectively inhibits 11β-HSD1 (IC50 = 0.7 μM).